Form 8-K - Current report:
SEC Accession No. 0001213900-26-046671
Filing Date
2026-04-22
Accepted
2026-04-22 17:06:06
Documents
12
Period of Report
2026-04-17
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea028720301-8k_apimeds.htm   iXBRL 8-K 29179
2 PRESS RELEASE DATED APRIL 21, 2026 ea028720301ex99-1_apimeds.htm EX-99.1 9571
  Complete submission text file 0001213900-26-046671.txt   209810

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE apus-20260417.xsd EX-101.SCH 3008
4 XBRL LABEL FILE apus-20260417_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE apus-20260417_pre.xml EX-101.PRE 22354
15 EXTRACTED XBRL INSTANCE DOCUMENT ea028720301-8k_apimeds_htm.xml XML 3332
Mailing Address 100 MATAWAN RD SUITE 325 MATAWAN NJ 07747
Business Address 100 MATAWAN RD SUITE 325 MATAWAN NJ 07747 848-201-5010
Apimeds Pharmaceuticals US, Inc. (Filer) CIK: 0001894525 (see all company filings)

EIN.: 851099700 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42545 | Film No.: 26884631
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)